Skip to main content

What’s the difference between Eylea, Eylea HD, and Avastin?

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 11, 2025.

Official Answer by Drugs.com

Eylea, Eylea HD, and Avastin may all be used to treat neovascular (wet) age-related macular degeneration (AMD), as injections into the eye (intravitreal injections). Both Eylea and Eylea HD are FDA-approved for this indication, but use of Avastin is off-label (not an FDA-approved indication - although it has been used for this purpose since 2005). Eylea HD is a longer acting version of Eylea (see What is the difference between Eylea and Eylea HD?).

They are all VEGF inhibitors and work by blocking VEGF, a signal protein that stimulates the growth of new blood vessels. Abnormal blood vessel growth from existing blood vessels (called angiogenesis) is associated with the progression of degenerative eye conditions such as neovascular AMD.

The main differences between Eylea, Eylea HD, and Avastin are:

Key Facts: Eylea Vs Avastin

Eylea Eylea HD Avastin
Generic name aflibercept aflibercept bevacizumab
Company Regeneron Regeneron Genentech
FDA approval date 2011 2023
  • Not FDA-approved for neovascular AMD but has been used since 2005
  • FDA approved for several cancers since 2004
Generic availability No generic No generic No generic
Drug class VEGF inhibitor (anti-angiogenic ophthalmic agent) VEGF inhibitor (anti-angiogenic ophthalmic agent) VEGF/VEGFR inhibitor
Dosage form Intravitreal injection Intravitreal injection Injection: 100 mg/4 mL (must be drawn up for intravitreal injection. Usual dose is 0.1ml [2.5mg])
Use
  • Neovascular AMD
  • DME
  • Macular edema following retinal vein occlusion
  • Diabetic retinopathy (DR)
  • Preterm infants with retinopathy of prematurity
  • Neovascular AMD (wAMD)
  • DME
  • Diabetic retinopathy (DR)
  • Use for Neovascular AMD is off label
  • Also used off-label for macular edema, diabetic retinopathy, and retinal vein occlusion
  • Several cancers (eg, colorectal cancer, NSCLC, ovarian cancer; see here for full prescribing information)
Dosing schedule and administration
  • Initially every 4 weeks then 4-12 weekly thereafter (depending on the condition)
  • Treatment holidays may be possible for eyes that have stabilized
  • Preterm infants: 0.4mg bilaterally on the same day; may be repeated after 10 days
  • Initially every 4 weeks for the first 3 doses, then once every 8 to 12 weeks for DR or 8 to 16 weeks for wAMD and DME
  • Every 4 to 6 weeks
  • Treatment holidays may be possible for eyes that have stabilized
Common side effects (>5% of patients)
  • Conjunctival hemorrhage
  • Eye pain
  • Cataract
  • Increased intraocular pressure
  • Vitreous detachment
  • Vitreous floaters
  • Red eye
  • Conjunctival hemorrhage
  • Eye pain
  • Cataract
  • Increased intraocular pressure
  • Vitreous detachment
  • Vitreous floaters
  • Red eye
  • Red eye
  • Dry or itchy eyes
  • Feeling like something is in the eye
  • Eye discomfort
  • Temporary blurred vision
  • Floaters
Warnings and precautions
  • Endophthalmitis
  • Retinal detachments
  • Increases in intraocular pressure within 60 minutes of administration
  • Arterial thromboembolic events
  • Endophthalmitis
  • Retinal detachments
  • Increases in intraocular pressure within 60 minutes of administration
  • Arterial thromboembolic events
  • Endophthalmitis
  • Retinal detachments
  • Eye infection
  • Eye pain
Cost
  • $2000 per treatment
  • $2600 per treatment
  • $100 per treatment

Related questions

References
  • Yorston D. (2014). Intravitreal injection technique. Community eye health, 27(87), 47.
  • Cao X, Castillo Sanchez J, Patel T, et al. Aflibercept is more effective than bevacizumab at weaning neovascular age-related macular degeneration patients off therapy
  • Eylea HD. Prescribing Information. https://www.regeneron.com/downloads/eyleahd_fpi.pdf
  • Eylea Prescribing Information. https://www.regeneron.com/downloads/eylea_fpi.pdf

Read next

What is the difference between Vabysmo and Eylea?

Vabysmo (faricimab) targets vascular endothelial growth factor (VEGF) and angiopoietin-1, whereas Eylea (afibercept) targets VEGF and placental growth factor (P1GF). Both agents are used to treat conditions such as macular degeneration (AMD) and diabetic macular edema and are given by intravitreal injection (into the gel part of the eye). Continue reading

What are anti-VEGF drugs (VEGF inhibitors)?

Anti-VEGF drugs slow the abnormal growth of blood vessels associated with certain cancers and degenerative eye conditions, such as age-related macular degeneration. Anti-VEGF stands for anti-vascular endothelial growth factor. Continue reading

How long does Eylea or Eylea HD take to work?

Eylea and Eylea HD usually work within 3 months, with some people noticing improvements in as little as one month of treatment, depending on the condition being treated. For some conditions, it may take up to 6 months before a significant difference is seen. Continue reading

See also:

Related medical questions

Drug information

Related support groups